Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer
of Listing.
On August 14, 2008, Vion Pharmaceuticals, Inc. (the “Company”), announced that the Company had
received a letter from NASDAQ on August 13, 2008 informing the Company that it would be delisted
from the Nasdaq Stock Market and trading in its shares would be suspended effective the open of
business on August 15, 2008. As stated in the letter, trading in the shares was suspended on the
Nasdaq Stock Market on August 15, 2008. The Company’s common stock is currently quoted on the Pink
Sheets. The Company is working with a market maker that has advised the
Company that it has filed a Form 211 with Financial Industry Regulatory Authority (FINRA) to seek
clearance to quote the Company’s common stock on the OTC Bulletin Board®.
A copy of the press release announcing the receipt of the delisting letter is attached hereto as
Exhibit 99.1 and is incorporated by reference herein.
| Item 9.01(d) | Exhibits. |
| Exhibit 99.1 | Press release dated August 14, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VION PHARMACEUTICALS, INC. |
||||
| Date: August 18, 2008 | By: | /s/ Howard B. Johnson | ||
| Name: | Howard B. Johnson | |||
| Title: | President and Chief Financial Officer | |||
EXHIBIT INDEX
| Exhibit 99.1 | Press release dated August 14, 2008. |